Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Wall Street Expects These Stocks to Soar 175% and 545%. Should You Buy?


Wall Street has high hopes for certain stocks over the coming 12 months. Two of them are biotech companies that took center stage during earlier days of the pandemic. I'm talking about (NASDAQ: NVAX) and Ocugen (NASDAQ: OCGN). Both companies raced to bring a coronavirus vaccine to market.

As it turns out, Novavax reached commercialization -- but later than today's market leaders, Pfizer and Moderna. And Ocugen dropped its flagship vaccine program and replaced it with earlier-stage work on inhaled-vaccine candidates.

Both stocks are falling in the double digits this year, and that's after poor performance last year. But could they be heading for a major rebound as Wall Street predicts? And should you get in on these recovery stories?

Continue reading


Source Fool.com

Novavax Inc. Stock

€11.81
1.440%
There is an upward development for Novavax Inc. compared to yesterday, with an increase of €0.17 (1.440%).
Currently there is a rather positive sentiment for Novavax Inc. with 5 Buy predictions and 1 Sell predictions.
As a result the target price of 21 € shows a very positive potential of 77.82% compared to the current price of 11.81 € for Novavax Inc..
Like: 0
Share

Comments